ZA200603904B - Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoy-lamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof - Google Patents

Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoy-lamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof Download PDF

Info

Publication number
ZA200603904B
ZA200603904B ZA200603904A ZA200603904A ZA200603904B ZA 200603904 B ZA200603904 B ZA 200603904B ZA 200603904 A ZA200603904 A ZA 200603904A ZA 200603904 A ZA200603904 A ZA 200603904A ZA 200603904 B ZA200603904 B ZA 200603904B
Authority
ZA
South Africa
Prior art keywords
combination
methyl
imatinib
inhibitor
leukemia
Prior art date
Application number
ZA200603904A
Other languages
English (en)
Inventor
Tim H Bruemmendorf
Balabanov Stefan
Hartmann Ulrike
Kammer Winfried
Nordheim Alfred
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200603904B publication Critical patent/ZA200603904B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200603904A 2003-12-19 2006-05-16 Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoy-lamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof ZA200603904B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19

Publications (1)

Publication Number Publication Date
ZA200603904B true ZA200603904B (en) 2007-09-26

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603904A ZA200603904B (en) 2003-12-19 2006-05-16 Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoy-lamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof

Country Status (17)

Country Link
US (1) US20080139480A1 (enExample)
EP (1) EP1696917A1 (enExample)
JP (1) JP2007514699A (enExample)
KR (1) KR20060125810A (enExample)
CN (1) CN1889952A (enExample)
AU (2) AU2004298761A1 (enExample)
BR (1) BRPI0417759A (enExample)
CA (1) CA2547196A1 (enExample)
EC (1) ECSP066656A (enExample)
IL (1) IL176070A0 (enExample)
MA (1) MA28240A1 (enExample)
MX (1) MXPA06006925A (enExample)
NO (1) NO20063326L (enExample)
RU (1) RU2006125741A (enExample)
TN (1) TNSN06182A1 (enExample)
WO (1) WO2005058320A1 (enExample)
ZA (1) ZA200603904B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2197440T3 (pl) 2007-08-31 2013-05-31 Janssen Pharmaceutica Nv Kombinacje imazalilu i hydroksypirydonów
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
WO2009098243A1 (en) * 2008-02-06 2009-08-13 Janssen Pharmaceutica Nv Combinations of anilinopyrimidines and pyrion compounds
WO2009098245A2 (en) 2008-02-06 2009-08-13 Janssen Pharmaceutica Nv Combinations of phenylpyrroles and pyrion compounds
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
CN104926722A (zh) * 2010-06-01 2015-09-23 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
MX342465B (es) * 2010-06-01 2016-09-30 Biotheryx Inc * Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.
EP2579718B1 (en) 2010-06-10 2014-10-01 Janssen Pharmaceutica, N.V. Combinations of pyrimethanil and monoterpenes
JP5870101B2 (ja) 2010-07-01 2016-02-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ピリオン化合物とポリエチレンイミンとの抗微生物性組み合わせ
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
ES2331562T3 (es) * 2001-03-23 2010-01-08 Enzon, Inc. Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.
WO2004007676A2 (en) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Also Published As

Publication number Publication date
AU2009201694A1 (en) 2009-05-28
WO2005058320A1 (en) 2005-06-30
MA28240A1 (fr) 2006-10-02
IL176070A0 (en) 2006-10-05
CA2547196A1 (en) 2005-06-30
BRPI0417759A (pt) 2007-04-10
NO20063326L (no) 2006-09-19
ECSP066656A (es) 2006-10-25
MXPA06006925A (es) 2006-08-23
TNSN06182A1 (en) 2007-11-15
RU2006125741A (ru) 2008-01-27
EP1696917A1 (en) 2006-09-06
JP2007514699A (ja) 2007-06-07
KR20060125810A (ko) 2006-12-06
AU2004298761A1 (en) 2005-06-30
CN1889952A (zh) 2007-01-03
US20080139480A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
AU2009201694A1 (en) Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
Lara Jr et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial
EP1250140B1 (en) Combination ofan abl-, pdgf-receptor- and/or kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein
JP6532878B2 (ja) 組合せ医薬
TWI449525B (zh) 治療癌症之相乘醫藥組合
RU2438664C2 (ru) Синергическая фармацевтическая комбинация для лечения рака
Karp et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
US20110098318A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
Cho et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
BRPI0620058A2 (pt) combinação farmacêutica compreendendo compostos inibidores da ligação da proteìna smac a proteìnas inibidoras de apoptose, e um taxano, bem como uso da mesma
Wagner et al. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour
US20220193076A1 (en) Methods of treating breast cancer with tucatinib
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
CA3236828A1 (en) Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers
JP7571024B2 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
US7799788B2 (en) Method of treating chronic myelogenous leukemia cells
US7045523B2 (en) Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
Park et al. The role of autophagy induced by pemetrexed in lung adenocarcinoma cells
EP1667719B1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
JP2007145745A (ja) 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
JP2009504674A (ja) 有機化合物の組合せ
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of